Filing Overview
Registrant: Foresight Acquisition Corp., not P3 Health Partners Inc. The Form 8-K reports events occurring on February 12, 2021, and was signed on February 19, 2021. Foresight completed its initial public offering and related private placement as a special purpose acquisition company.
Transaction and Financial Metrics
- IPO: 31,625,000 units sold at $10.00 per unit, generating gross proceeds of $316.25 million. The amount includes 4,125,000 units issued upon the underwriters’ full exercise of their over-allotment option.
- Unit structure: Each unit consisted of one share of Class A common stock and one-third of one redeemable warrant. Each whole warrant is exercisable for one share at $11.50, subject to adjustment.
- Private placement: 832,500 private placement units sold at $10.00 per unit, generating gross proceeds of $8.325 million.
- Trust account: $316.25 million of net proceeds from the IPO and private placement was deposited into a trust account for the benefit of public stockholders.
- Revenue, profit, cash flow, margins, and debt: The filing does not provide operating results or clear values for these metrics. It instead includes an audited balance sheet as of February 12, 2021 as Exhibit 99.1.
Material Changes and Outlook
The principal reported change is the completion of Foresight’s IPO, the full exercise of the underwriters’ over-allotment option, and the simultaneous private placement. The filing does not provide guidance, acquisition timing, management outlook, or a discussion of operating risks, contingencies, or unusual items beyond the transaction details.
Investor Verification Items
- Confirm the registrant’s identity: the filing is for Foresight Acquisition Corp., while the request metadata identifies P3 Health Partners Inc.
- Review Exhibit 99.1 for the audited balance sheet and the detailed composition of cash, offering costs, and other liabilities.
- Verify the trust-account amount and the terms of public and private securities, including redemption provisions and warrant adjustments.
- Assess subsequent filings for any announced business combination, target company, or changes to the SPAC’s transaction timetable.